Ting Cheng: Why Gene Therapy Needs Reinvention Before It Can Reach Millions
Ting Cheng, Principal Scientist at Johnson & Johnson, AI/Tech and Pharma/Healthcare Investor, shared on LinkedIn:
”Pfizer approved a hemophilia gene therapy in 2025.
Then pulled it — because not a single patient ever received it after approval.
In that same seven-month window, five major pharma companies spent over $10 billion acquiring pre-commercial cell therapy companies, before any of them had treated a paying patient.
Both things are true at once, and the article breaks down what that actually means: the current generation’s manufacturing and pricing model is broken, not the underlying biology — which already has 34,000 treated patients and 14 billion USD in 2024 revenue behind five approved drugs.
The next wave is targeting something structurally different — a $150 billion market the current approach was never built to reach.
Read the full breakdown here.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI